<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70465">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01864941</url>
  </required_header>
  <id_info>
    <org_study_id>H12-01153</org_study_id>
    <nct_id>NCT01864941</nct_id>
  </id_info>
  <brief_title>Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients</brief_title>
  <official_title>Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multiple Sclerosis Society of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and tolerability of balloon venoplasty compared to sham in
      Multiple Sclerosis patients with Chronic Cerebrospinal Venous Insufficiency (CCSVI) as
      measured by adverse events occurring within 48 weeks of the procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview of study objectives are:

        -  To determine the safety and tolerability of venoplasty of CCSVI in Multiple Sclerosis
           (MS).

        -  To determine the short term and long term impact on validated patient measures and by
           physician and radiologic reported MS outcomes.

        -  To determine the short term and long term recurrence rate of CCSVI for veins that have
           been treated with venoplasty
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To investigate the safety and tolerability of balloon venoplasty compared to sham in Multiple Sclerosis (MS) patients with CCSVI as measured by adverse events occurring within 48 weeks of the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by patient reported quality of life, pain and fatigue scales  48 weeks after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by physician reported clinical scales  48 weeks after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by MRI 48 weeks after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the efficacy of balloon venoplasty compared to sham as reflected by catheter venography 48 weeks after the procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Catheter Venography &amp; Balloon Venoplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo catheter venography with balloon venoplasty procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter Venography Only</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will undergo catheter venography only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter venography with balloon venoplasty</intervention_name>
    <description>All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.</description>
    <arm_group_label>Catheter Venography &amp; Balloon Venoplasty</arm_group_label>
    <arm_group_label>Catheter Venography Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter venography with balloon venoplasty and balloon</intervention_name>
    <arm_group_label>Catheter Venography &amp; Balloon Venoplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) or Secondary   Progressive
             MS according to the McDonald criteria 2010

          -  Age 18 to 65 years inclusive

          -  Neurostatus (EDSS) score at screening from 0 to 6.5

          -  Fulfill ultrasound criteria for CCSVI

        Exclusion Criteria:

          -  Previous venoplasty and/or stenting of extra cranial venous system
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Traboulsee, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Harvey</last_name>
    <email>ccsvi@brain.ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Tzeng</last_name>
    <email>ccsvi@brain.ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver Coastal Health - University of British Columbia Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Harvey</last_name>
      <email>ccsvi@brain.ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Tzeng</last_name>
      <email>ccsvi@brain.ubc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Traboulsee, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Hall</last_name>
      <email>ccsvi@hsc.mb.ca</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Stanger</last_name>
      <email>ccsvi@hsc.mb.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Reza Vosoughi, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guylaine Lucier</last_name>
      <email>guylaine.lucier.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Marc Girard, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec - Hôpital de l'Enfant-Jésus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Morel</last_name>
      <email>lucie.morel.cha@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Francois Emond, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.vchri.ca/s/MS-CCSVI-LATEST.asp</url>
    <description>Vancouver Coastal Health Research Institute - CCSVI Webpage</description>
  </link>
  <link>
    <url>http://www.cihr-irsc.gc.ca/e/45919.html</url>
    <description>Canadian Institutes of Health Research - CCSVI Trial News Release</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>May 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>CCSVI</keyword>
  <keyword>Zamboni</keyword>
  <keyword>catheter venography</keyword>
  <keyword>balloon angioplasty</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
